Answers are grounded in this paper and cite their sources.
Severe traumatic brain injury (sTBI) represents a leading cause of trauma-related mortality and long-term disability worldwide, with raised intracranial pressure (ICP) and secondary brain injury constituting the primary drivers of poor prognosis. Sedation serves as a cornerstone of sTBI management by mitigating stress responses, reducing cerebral metabolic demand, and facilitating ICP control, yet its clinical application remains complicated by heterogeneous drug pharmacokinetics, dynamic neurophysiological goals, and limited high-quality evidence guiding agent selection. While short-acting agents such as propofol and remifentanil are favored for their titratability and rapid offset, controversies persist regarding optimal sedation depth, duration, and the balance between neuroprotection and oversedation-related complications. In this review, we synthesize current evidence on the pathophysiology underpinning sedation use in sTBI, evaluate the pharmacological profiles of commonly employed sedatives—including volatile anesthetics, intravenous hypnotics, and analgesics—and discuss emerging strategies for personalized sedation management guided by multimodal neuromonitoring. We further highlight critical knowledge gaps and propose directions for future translational research to refine sedation protocols and improve functional outcomes in sTBI populations.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: